Compensatory mechanisms enhance hippocampal acetylcholine release in transgenic mice expressing human acetylcholinesterase.
Central cholinergic neurotransmission was studied in learning-impaired transgenic mice expressing human acetylcholinesterase (hAChE-Tg). Total catalytic activity of AChE was approximately twofold higher in synaptosomes from hippocampus, striatum and cortex of hAChE-Tg mice as compared with controls (FVB/N mice). Extracellular acetylcholine (ACh) levels in the hippocampus, monitored by microdialysis in the absence or presence of 10(-8)-10(-3) M neostigmine in the perfusion fluid, were indistinguishable in freely moving control and hAChE-Tg mice. Muscarinic receptor functions were unchanged as indicated by similar effects of scopolamine on ACh release and of carbachol on inositol phosphate formation. However, when the mice were anaesthetized with halothane (0.8 vol. %), hippocampal ACh reached significantly lower levels in AChE-Tg mice as compared with controls. Also, the high-affinity choline uptake (HACU) in hippocampal synaptosomes from awake hAChE-Tg mice was accelerated but was reduced by halothane anaesthesia. Moreover, hAChE-Tg mice displayed increased motor activity in novel but not in familiar environment and presented reduced anxiety in the elevated plus-maze test. Systemic application of a low dose of physostigmine (100 microgram/kg i.p.) normalized all of the enhanced parameters in hAChE-Tg mice: spontaneous motor activity, hippocampal ACh efflux and hippocampal HACU, attributing these parameters to the hypocholinergic state due to excessive AChE activity. We conclude that, in hAChE-Tg mice, hippocampal ACh release is up-regulated in response to external stimuli thereby facilitating cholinergic neurotransmission. Such compensatory phenomena most likely play important roles in counteracting functional deficits in mammals with central cholinergic dysfunctions.
Erb
C
C
Department of Pharmacology, University of Mainz, Mainz, Germany.
Troost
J
J
Kopf
S
S
Schmitt
U
U
Löffelholz
K
K
Soreq
H
H
Klein
J
J
D000109:Acetylcholine / Q000378:metabolism*; D000110:Acetylcholinesterase / Q000235:genetics / Q000378:metabolism*; D000375:Aging / Q000378:metabolism; D018685:Anesthetics, Inhalation / Q000494:pharmacology; D000818:Animals; D002794:Choline / Q000493:pharmacokinetics; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D003072:Cognition Disorders / Q000201:enzymology / Q000235:genetics* / Q000378:metabolism; D004195:Disease Models, Animal; D005106:Exploratory Behavior; D005110:Extracellular Space; D005813:Genes, Synthetic; D006221:Halothane / Q000494:pharmacology; D006624:Hippocampus / Q000201:enzymology / Q000378:metabolism*; D006706:Homeostasis; D006801:Humans; D007295:Inositol Phosphates / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D017551:Microdialysis; D009043:Motor Activity / Q000187:drug effects; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism*; D010830:Physostigmine / Q000494:pharmacology; D011401:Promoter Regions, Genetic; D012636:Secretory Rate; D013045:Species Specificity; D013574:Synaptosomes / Q000201:enzymology; D019076:Transgenes
D018685:Anesthetics, Inhalation; D002800:Cholinesterase Inhibitors; D007295:Inositol Phosphates; D009419:Nerve Tissue Proteins; D010830:Physostigmine; D000110:Acetylcholinesterase; D002794:Choline; D000109:Acetylcholine; D006221:Halothane